Your browser is no longer supported. Please, upgrade your browser.
CATB Catabasis Pharmaceuticals, Inc. monthly Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own0.13% Shs Outstand20.08M Perf Week-3.55%
Market Cap27.70M Forward P/E- EPS next Y-0.86 Insider Trans0.00% Shs Float20.06M Perf Month-76.95%
Income-34.90M PEG- EPS next Q-0.41 Inst Own51.00% Short Float3.21% Perf Quarter-83.41%
Sales- P/S- EPS this Y54.10% Inst Trans2.73% Short Ratio0.54 Perf Half Y-77.81%
Book/sh2.54 P/B0.54 EPS next Y56.10% ROA-65.00% Target Price- Perf Year-72.75%
Cash/sh- P/C- EPS next 5Y- ROE-73.70% 52W Range1.25 - 8.59 Perf YTD-76.99%
Dividend- P/FCF- EPS past 5Y31.70% ROI- 52W High-83.47% Beta1.98
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low13.60% ATR0.25
Employees27 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)21.12 Volatility4.84% 7.88%
OptionableYes Debt/Eq0.00 EPS Q/Q0.20% Profit Margin- Rel Volume1.63 Prev Close1.36
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.18M Price1.42
Recom3.00 SMA20-10.38% SMA50-67.92% SMA200-74.10% Volume1,342,393 Change4.41%
Nov-02-20Downgrade Wedbush Outperform → Neutral
Oct-27-20Downgrade Oppenheimer Outperform → Perform
Oct-27-20Downgrade H.C. Wainwright Buy → Neutral
Oct-01-20Initiated H.C. Wainwright Buy $24
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Nov-12-20 04:10PM  
Oct-28-20 07:41AM  
Oct-27-20 08:24AM  
Oct-26-20 05:00PM  
Sep-28-20 08:00AM  
Sep-23-20 08:00AM  
Sep-21-20 08:00AM  
Sep-10-20 08:51AM  
Sep-08-20 08:00AM  
Sep-03-20 08:41AM  
Sep-02-20 08:00AM  
Aug-25-20 08:38AM  
Aug-21-20 10:35AM  
Aug-10-20 04:10PM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-27-20 08:00AM  
Jul-15-20 08:00AM  
Jun-29-20 04:10PM  
Jun-15-20 08:16PM  
Jun-12-20 08:00AM  
May-12-20 04:10PM  
08:00AM  
May-07-20 09:30AM  
Apr-28-20 08:00AM  
Apr-17-20 08:00AM  
Mar-27-20 03:22AM  
Mar-25-20 08:00AM  
Mar-24-20 04:00PM  
Mar-18-20 08:00AM  
Mar-14-20 09:32AM  
Mar-10-20 08:05AM  
06:30AM  
Feb-25-20 08:00AM  
Feb-21-20 08:00AM  
Feb-03-20 04:05PM  
Jan-30-20 09:00AM  
Jan-29-20 04:01PM  
06:10AM  
Jan-09-20 04:09PM  
Jan-08-20 08:00AM  
Dec-24-19 06:15AM  
Dec-23-19 02:15PM  
Dec-16-19 08:00AM  
Nov-25-19 06:45PM  
Nov-18-19 06:53AM  
Nov-07-19 08:05AM  
Oct-24-19 08:00AM  
Oct-19-19 09:26AM  
Oct-18-19 08:00AM  
Oct-05-19 08:00AM  
Sep-30-19 04:05PM  
Sep-27-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-19-19 10:13AM  
Aug-20-19 10:58AM  
Aug-09-19 05:04PM  
Aug-08-19 08:05AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-25-19 08:30AM  
Jul-15-19 03:08PM  
Jun-27-19 08:00AM  
Jun-21-19 09:45AM  
Jun-18-19 08:00AM  
Jun-07-19 09:24AM  
May-15-19 06:33PM  
08:38AM  
May-14-19 08:05AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-26-19 03:26PM  
Apr-12-19 11:34AM  
Apr-01-19 08:00AM  
Mar-26-19 12:11PM  
08:07AM  
Mar-19-19 12:26PM  
Mar-18-19 09:02AM  
Mar-14-19 06:09PM  
08:30AM  
08:05AM  
Mar-13-19 08:00AM  
Mar-08-19 09:54AM  
Mar-07-19 08:57AM  
08:51AM  
Mar-06-19 01:56PM  
Feb-28-19 08:00AM  
Feb-19-19 08:00AM  
Feb-14-19 08:00AM  
Feb-06-19 09:00AM  
08:23AM  
Feb-05-19 04:01PM  
Jan-29-19 07:55AM  
Jan-15-19 11:10AM  
Jan-14-19 01:42AM  
Jan-11-19 09:30AM  
Jan-08-19 08:38AM  
Jan-04-19 08:00AM  
Jan-03-19 08:08AM  
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.